Some of the figures were produced with the help of Abhishek Garg using Servier Medical Art (available at www.servier.com) for which we would like to acknowledge Servier.
Article first published online: 26 MAY 2011
Copyright © 2011 American Cancer Society, Inc.
CA: A Cancer Journal for Clinicians
Volume 61, Issue 4, pages 250–281, July/August 2011
How to Cite
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., Korbelik, M., Moan, J., Mroz, P., Nowis, D., Piette, J., Wilson, B. C. and Golab, J. (2011), Photodynamic therapy of cancer: An update. CA: A Cancer Journal for Clinicians, 61: 250–281. doi: 10.3322/caac.20114
DISCLOSURES: Supported by the Fund for Scientific Research (FWO)-Flanders (Belgium) (grant numbers G.0661.09 and G.0728.10), the Interuniversity Attraction Pole IAP6/18 of the Belgian Federal Government, and the Catholic University of Leuven (OT/06/49 and GOA/11/009) (to P.A.); National Institutes of Health (NIH) grant CA-087971 (to K.A.C. and S.M.H.); NIH grants CA72630, CA70823, and HL85677 (to A.W.G.); NIH grants CA55791 and CA98156 (to S.O.G.); NIH grants CA68409 and CA122093 (to T.H.F.); NIH grants AI050875 and CA083882 (to M.R.H.); and the European Regional Development Fund through Innovative Economy grant POIG.01.01.02-00-008/08 (to J.G.). Dr. Kessel's research has been supported by NIH grants since 1980, predominantly by CA23378. Dr. Juzeniene' research has been supported by the Norwegian Cancer Society. Dr. Mroz was partly supported by a Genzyme-Partners Translational Research Grant. Dr. Golab is a recipient of the Mistrz Award from the Foundation for Polish Science and a member of the TEAM Programme cofinanced by the Foundation for Polish Science and the European Union European Regional Development Fund.
- Issue published online: 30 JUN 2011
- Article first published online: 26 MAY 2011
Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment. CA Cancer J Clin 2011. © 2011 American Cancer Society, Inc.